← Russell 3000 cross-section

CRBU Caribou Biosciences, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$180m
Revenue TTM
$10m
Net income TTM
$-103m
Free cash flow
$-96m
Composite score
34.1
Sector rank
#2912

Valuation

P / E
EV / EBITDA
EV / sales
6.7
FCF yield
-53.32%
Earnings yield vs 10-yr
-62.31pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,030.4%
EBITDA margin
-1,065.1%
ROE
-105.4%
ROIC
Revenue growth
10.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

To date, we have primarily funded our operations through proceeds from the sales of our capital stock, revenue from our license and collaboration agreements, and proceeds from the sale of shares of Intellia Therapeutics, Inc. Revenue under such agreements was $1.5 million and $2.7 million for the three months ended June 30, 2026, and June 30, 2025, respectively, and $3.9 million and $5.0 million for the six months ended June 30, 2026, and June 30, 2025, respectively. …Caribou Biosciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →